Methods: Our gel-free proteomics approach includes tissue extraction, digestion by trypsin and reversed phase separations coupled to tandem mass spectrometry for the identification and targeted quantification of peptides by multiple reaction monitoring (MRM). The tissue was sliced from synovial surface to bone in 10mm thin sections and the full thickness cartilage was divided into 100mm pools including superficial, intermediate and deep zones. Results: Previous known distribution of proteoglycan 4 (PRG4, lubricin, superficial zone protein) was confirmed but also novel findings were observed e.g. asporin which was predominantly present in the superficial layers. In total 40 proteins were quantified showing distinct patterns in normal tissue. In addition we observed altered protein distribution patterns in preclinical (macroscopically normal) tissue from a joint with early fibrillation (OA-lesions) on the opposite surface. Conclusions: As an alternative to immunohistochemistry we used proteomics technology to study the protein abundance across full thickness articular cartilage. The advantages of this approach are that it allows multiple targets to be studied simultaneously, it is independent of antibody availability and circumvent some antibody-related artifacts. Other advantages include unambiguous identifications and improved quantifications. The work shows novel information on the differences that exist in different layers of cartilage that is of value in understanding changes in early pathology.
Purpose: Biomarkers of cartilage inflammation and degradation can provide information about the pathogenesis of arthritic diseases such as osteoarthritis (OA), allowing earlier diagnosis, improved monitoring, and mechanistic insight into OA progression. Utilizing high-throughput proteomics approaches, this study aimed to identify and quantitatively compare proteins that respond to pro-inflammatory (IL-1b) and antiinflammatory (carprofen) stimuli in the secretome of articular cartilage. Methods: Articular cartilage was harvested from equine metacarpophalangeal joints from horses euthanized for purposes other than research. Explant cultures were established and treated as follows: untreated (control) media alone, pro-inflammatory cytokine IL-1b (10 ng/ml), the COX-2 specific non-steroidal anti-inflammatory drug (NSAID) carprofen (100 mg/ml) or IL-1b + carprofen. After 6 days incubation (37 C, 5% CO2) media were collected for downstream analysis, using a combination of SDS-PAGE, silver staining, high-throughput nanoLC-MS/MS on an amaZon speed ETD (Bruker) and quantitative western blotting. Results: High-throughput mass spectrometry identified cartilage extracellular matrix (ECM) proteins (biglycan, fibronectin, decorin, COMP, collagen type II), secreted proteins related to cartilage maintenance and turnover (MMP-1, -3 and -13, TIMP-1), along with inflammatory stress/molecular chaperone related proteins (HSP70, clusterin). Qualitative differences in PCPE-2, frizzled related protein, HSP70, MMP-1, -3 and -13 release were observed between untreated and cytokine treated explant secretomes. Quantitative analysis by western blotting confirmed that carprofen treatment significantly reduced IL-1b stimulated release of MMP-1, -3 and -13. ECM proteins targeted by these IL-1b-stimulated MMPs (i.e. fibronectin) exhibited additional fragmentation patterns on western blots, which were reduced by carprofen treatment.
Conclusions: Proteins differentially released in response to IL-1b stimulation within this explant model may enable screening of new and existing drugs and various natural compounds with anti-inflammatory properties. This study revealed that carprofen, a COX-2 specific inhibitor, decreases the release of inflammatory-associated proteins and one established BIPEDS marker of cartilage degradation in OA (MMP-3). Carprofen-suppression of IL-1b-stimulated MMP-1, -3 and -13 release may result in reduced ECM degradation indicating that this drug may potentially reduce progression of degenerative cartilage loss and OA. This interpretation of the data is supported by the reduction of IL-1b stimulated fibronectin degradation fragments released from the ECM. Combining high-throughput analytical techniques such as proteomics with this in vitro model of cartilage inflammation produces interpretable data and may provide realistic alternatives to in vivo animal models. Purpose: Osteoarthritis (OA) is characterized by the loss of structural components from the extracelullar matrix (ECM) of articular cartilage. The release of these proteins from the tissue can vary according to the stage of the disease. The aim of this study was to perform a proteomics approach to identify and quantify those proteins released from normal and OA human articular cartilage explants. Furthermore, we seeked to differentiate those proteomic signatures displayed from the wounded zones (WZ) from those corresponding to the area adjacent to the lesion, or unwounded zones (UZ), in the OA samples. These proteins released from cartilage might have a tissue-characteristic biomarker value for early diagnosis and/or therapy monitoring. Methods: Macroscopically articular cartilage was obtained from the dissection of normal and OA femoral heads. The cartilage from normal samples, and from WZ and UZ of the same OA piece, was cut into five 6mm2 explants. Then, these explants were washed in PBS and harvested in 96-well plates with 200mL of serum-free DMEM. The conditioned media from each condition were collected at days 1, 3, 6 and replaced with fresh medium. Media from each condition were quantified, concentrated and precipitated O/N with acetone. Finally, proteins were digested with trypsin and each peptide solution was labelled with different isobaric tags using the iTRAQ reagents. The labelled peptides of the different conditions were mixed, desalted and separated by HPLC. The resulting fractions were grouped and resolved by reversed-phase nanoliquid cromatography coupled to mass spectrometry. The identification and relative quantification of the proteins was carried out with Protein Pilot 3.0 software. Results: Protein concentrations were higher in the culture media from wounded zones than from unwounded zones of OA cartilage, due to the increased degradation that is taking place in the lesion. We first identified several ECM proteins that were differentially released between WZ and UZ in OA samples at two different times of culture. Most of them were increased in the wounded tissue, including collagens (I, II, VI and XV), proteoglycans (biglycan, lumican or perlecan) and proteins related with cell adhesion (tenascins, osteomodulin or vitronectin). In a second step, proteins released to the media up to day 6 of culture were compared between three conditions (WZ, UZ and normal tissue). This analysis led to the identification of 199 proteins, 110 of them quantitatively altered between the conditions of the study. Interestingly, several proteins were differentially released already in the unwounded zone of OA cartilage compared to the normal samples (osteopontin, matrilin-3, cartilage link protein or transforming growth factor-beta-induced protein), and their amounts do not seem to be increased in the WZ. Finally, a small set of proteins, including thrombospondin-1 or type XVIII collagen, were more abundant in the media from N cartilage than from OA. Conclusions: We have identified a profile of proteins released from diseased cartilage in OA. Our work describes a panel of cartilage-characteristic proteins with potential biomarker value of the tissue degradation process that takes place in the disease. This panel will be further explored in biological fluids (synovial fluid and serum) for the development of early diagnosis and/or therapy monitoring strategies.
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